Main contents starts here
Press Releases 2003
- December 25, 2003
Takeda Establishes New Global Pharmaceutical R&D Center in US - December 18, 2003
Lilly and Takeda sign a Joint Development/Co-Marketing Agreement on Ruboxistaurin Mesylate, an agent for the treatment of diabetic microvascular complications - November 4, 2003
TPNA to Start Co-Promotion for Two Products for Treatment of Cholesterol Disorders - October 22, 2003
Takeda Files Patent Infringement Litigation Against ANDA Submissions for Generic Pioglitazone - September 30, 2003
Peninsula Pharmaceuticals, Inc. and Takeda Chemical Industries, Ltd. Announce North American, European and Pan-Pacific Collaboration for TAK-599 Anti-MRSA Cephalosporin Antibiotic - September 25, 2003
Discontinuation of Development of Anti-Diabetic Agent AJ-9677/TAK-677 - September 24, 2003
New Structure for Pharmaceutical Marketing Division - September 3, 2003
Actos Approved for Monotherapy for Defined Patients with Type 2 Diabetes in Europe - August 31, 2003
CHARM* Programme demonstrates clear benefits of candesartan in the treatment of symptomatic heart failure
Candesartan is the first and only Angiotensin Receptor Blocker (ARB) proven to reduce cardiovascular death and hospitalisation in chronic heart failure when given together with conventional therapy - August 1, 2003
Evotec Neurosciences And Takeda Enter Into Drug Discovery Alliance In Alzheimer's Disease - August 1, 2003
Kirin Licenses Human Antibody Technology To Takeda - July 29, 2003
Takeda to Increase Capital of Takeda America Holdings, Inc. - July 23, 2003
Summary of Consolidated Financial Results for the Fiscal 2003 First Quarter (from April 1 to June 30, 2003) - June 27, 2003
Takeda to Re-organize International Business into Regional Unit - June 2, 2003
Actos Receives CPMP's Recommendation for Monotherapy for Defined Patients with Type 2 Diabetes - May 21, 2003
Wyeth and Takeda Sign New Partnership Agreements - May 16, 2003
Notice regarding Acquisition of the Company's own shares
(Acquisition of the Company's own shares pursuant to the provisions of Article 210 of the Commercial Code of Japan) - April 22, 2003
Takeda announced the change of Chairman of the Board and President - February 24, 2003
Takeda Discovered a Novel Mechanism of Insulin Secretion through a Fatty Acid Receptor GPR40 - February 12, 2003
Takeda Presents pharmacological data on its oral CCR5 antagonist at Retrovirus and Opportunistic Infections Conference - January 29, 2003
Takeda's Life-Environment business unit to become a wholly-owned subsidiary - January 28, 2003
Sales of Main Products and Updates of R&D Pipeline Stage in Third-Quarter FY2002 (October 1 - December 31, 2002) - January 10, 2003
Takeda Chemical Industries and Beth Israel Deaconess Medical Center Announce Collaborative Agreement for Metabolic Disease Research